Mabion S.A. (WSE:MAB)

Poland flag Poland · Delayed Price · Currency is PLN
9.67
-0.03 (-0.31%)
Jun 6, 2025, 4:44 PM CET
-45.86%
Market Cap 155.80M
Revenue (ttm) 37.76M
Net Income (ttm) -39.13M
Shares Out 16.16M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,910
Average Volume 33,947
Open 9.67
Previous Close 9.70
Day's Range 9.57 - 9.75
52-Week Range 8.38 - 20.45
Beta 0.18
RSI 42.11
Earnings Date May 20, 2025

About Mabion

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. It also offers clinical and commercial drug substance manufacturing of therapeutic proteins using mammalian and insect cell cultures, including biosimilars, monoclonals, vaccine antigens, and other recombinant proteins. Its products include MabionCD20 and MabionHER2. Mabion... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 213
Stock Exchange Warsaw Stock Exchange
Ticker Symbol MAB
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.